Physician profile
Jonathan L Ives
NPI 1225412356
$791.29
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.27 · 2022: $154 · 2023: $74.08 · 2024: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $418.85 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $40.53 | 2023-2024 | Impella |
| Glaxosmithkline, LLC. | $35.24 | 2022-2024 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $34.13 | 2022 | |
| Shionogi INC | $28.08 | 2023 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $27.45 | 2021 | |
| Ani Pharmaceuticals, INC. | $26.18 | 2024 | Purified Cortrophin Gel |
| Atricure, INC. | $25.92 | 2023 | |
| Amgen INC. | $22.94 | 2022 | |
| Mylan Specialty L.P. | $19.28 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $17.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.07 | 2022 | |
| Pfizer INC. | $16.64 | 2021 | |
| Teleflex LLC | $16.18 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $15.14 | 2022 | |
| Insmed, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Ives listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.